Investor Relations


Welcome to Trovagene Investor Relations

Corporate Profile

Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring® (PCM) technology for the detection and monitoring of circulating tumor DNA (ctDNA) in urine and blood. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s PCM technology is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally. 

Trovagene Corporate Presentation
September 12, 2016 - September 13, 2016

Trovagene's Chief Scientific Officer, Mark Erlander, Ph.D. will be presenting; Clinical Utility for Detection and Monitoring Circulating Tumor DNA from Urine and Plasma, at the 3rd Precision...

print email